[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100345493":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":40,"collaborators":7,"id":42,"slug":7,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":7,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":7,"enrollmentInfo":7,"targetDuration":7,"studyType":50,"phases":7,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Eisai Inc.","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DRUG","Rufinamide","Rufinamide up to 45 milligram per kilogram per day (mg\u002Fkg\u002Fday).",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Eisai Medical Information","CONTACT","1-888-274-2378","esi_medinfo@eisai.com",[20,32],{"facility":21,"status":22,"city":23,"state":7,"zip":7,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":7},"Generała Tadeusza Kościuszki 52","AVAILABLE","Kielce","Poland","PL",{"type":27,"coordinates":28},"Point",[29,30],20.62752,50.87033,{"lat":30,"lon":29},{"facility":33,"status":22,"city":34,"state":7,"zip":7,"country":24,"countryCode":25,"cosmosGeoPoint":35,"geoPoint":39,"contacts":7},"Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu","Poznan",{"type":27,"coordinates":36},[37,38],16.92993,52.40692,{"lat":38,"lon":37},{"type":41,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100345493",false,"NCT03778424","An Extended Access Program (EAP) for Participants Who Have Completed Rufinamide Study E2080-G000-303","An Extended Access Program (EAP) for Rufinamide in Pediatric Participants With Inadequately Controlled Lennox-Gastaut Syndrome","Inclusion Criteria:\n\n* Participants who were on rufinamide treatment and have completed Study E2080-G000-303 in Poland.\n\nExclusion Criteria:\n\n* Participants were randomized to the other antiepileptic drug (AED) treatment group in study E2080-G000-303.","ALL","4 Years","EXPANDED_ACCESS","This is an extended access study for participants who have completed Rufinamide Study E2080-G000-303 to continue to have access to rufinamide until it becomes commercially available in Poland or until no participants remain in the EAP.",[53],"Lennox Gastaut Syndrome",[55,56,11,57,58,59],"Central Nervous System","E2080","Epilepsy","Seizures","Brain Diseases","2025-07-14",{"date":62,"type":63},"2025-07-17","ACTUAL",{"name":5,"class":6},2]